LTRN Latest Press Releases

-- October 8, 2026 --

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 Business Wire 8:00 AM

-- October 7, 2026 --

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC Business Wire 8:31 AM

-- September 30, 2026 --

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering Business Wire 4:01 PM

-- September 29, 2026 --

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering Business Wire 8:08 AM

-- September 23, 2026 --

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET Business Wire 7:45 AM

-- September 22, 2026 --

Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas Business Wire 7:45 AM

-- September 17, 2026 --

Lantern Pharma to Present Open-Medicine AI - a Multi-Agentic Platform for End-to-End Therapeutic Development - Business Model, Roadmap, and Value Proposition on September 23 Business Wire 8:20 AM

-- August 14, 2026 --

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire 7:30 AM

-- August 7, 2026 --

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET Business Wire 8:00 AM

-- August 3, 2026 --

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine Business Wire 7:30 AM

-- July 28, 2026 --

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer Business Wire 7:45 AM

-- July 23, 2026 --

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers Business Wire 8:01 AM

-- July 8, 2026 --

Lantern Pharma Launches ZetaOmics - an Autonomous, Intelligent 'Computational Biologist' That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer Business Wire 7:30 AM

-- June 2, 2026 --

Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer Business Wire 8:13 AM

Market Data Delayed 15 Minutes